Kinaset Therapeutics
PrivateLast Round
Series B
Jan 10, 2026
Total Funding Raised
$171.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Kinaset Therapeutics operates in Healthcare & Life Sciences and is based in Medfield, Massachusetts. Its latest recorded funding round was a Series B round in January 2026.
Kinaset Therapeutics is a biopharmaceutical company that develops inhaled therapeutics for serious respiratory diseases, including severe asthma.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Kinaset Therapeutics Comparables
Compare Kinaset Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sensory Cloud Inc. | 81% | |
| Areteia Therapeutics | 81% | |
| RaeSedo, Inc. | 77% |
For institutional investors. Book with your work email.
Kinaset Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 10, 2026 | ||||
| Series A Extension | Jul 18, 2022 | ||||
| Series A | Nov 30, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Kinaset Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series B |
| Sixty Degree Capital | Series B |
| EQT Life Sciences | Series B |
| SV Health Investors | Series A Extension |
| Gimv | Series B, Series A, Series A Extension |
| 5AM Ventures | Series B, Series A Extension, Series A |
| Accomplice | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 271% MoM, reaching 2.4K.
- Jan 12, 2026
Daniela Begolo from EQT Life Sciences joins the board.
For institutional investors. Book with your work email.
Kinaset Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Kinaset Therapeutics's valuation, stock price, and market status.
Is Kinaset Therapeutics a public or private company?
Kinaset Therapeutics is a private company.
What is the current stock price of Kinaset Therapeutics?
Kinaset Therapeutics is a private company, so its shares have no public market price. Caplight tracks Kinaset Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Kinaset Therapeutics worth (valuation)?
Valuation information for Kinaset Therapeutics is not publicly available.
Can I buy Kinaset Therapeutics stock?
Kinaset Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Kinaset Therapeutics's last funding round?
Kinaset Therapeutics's most recent funding round was Series B on January 10, 2026.
Who are the main investors in Kinaset Therapeutics?
Key investors in Kinaset Therapeutics include RA Capital Management, 5AM Ventures, Forge Life Science Partners, Atlas Venture.
Will Kinaset Therapeutics IPO soon?
No public IPO plans have been announced for Kinaset Therapeutics.
How can I track Kinaset Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Kinaset Therapeutics's shares on secondary markets.